Abstract

Most of the treatments for osteoarthritis at recent times are palliative and mainly treat the symptoms rather than influencing the biochemical environment of the joint. Meanwhile, autologous platelet-rich plasma has emerged as a treatment option for tendinopathies and chronic wounds. After obtaining clearance and approval from the institutional ethical committee and patients fulfilling the inclusion criteria were considered for the study after obtaining informed consent. The demographic data and relevant history of the study participants were collected, and necessary clinical and radiological examination was performed. The mean VAS score of the study participants at the baseline was 6.54 with a standard deviation of around ±0.719. This implies that the study participants were experiencing more pain before the intervention. Later, the follow up was made on 3 different occasions. The variation in VAS scores from the baseline was compared in each follow up i.e., 6 weeks, 3 months, and 6 months after the intervention. In the study, the mean WOMAC score of the participants at the baseline was 71.07 with a standard deviation of around ±3.826. This implies that the study participants were experiencing more pain, increased stiffness, and disturbed function of the joint before the intervention. Later, the follow up was made on 3 different occasions. The variation in WOMAC scores from the baseline was compared in each follow up i.e., 6 weeks, 3 months, and 6 months after the intervention

Description